Logo
x

Search category

Subscribe Now

Bayer

Bayer’s BlueRock Reports the P-I Study Data for Bemdaneprocel (BRT-DA01) Stem Cell Therapy to Treat Parkinson’s Disease

Bayer’s BlueRock Reports the P-I Study Data for Bemdaneprocel (BRT-DA01) Stem Cell Therapy to Treat Parkinson’s Disease

  • June 29, 2023
Bayer Reports the Initiation of the P-III (QUANTI) Trials for Gadoquatrane as a Contrast Agent for Magnetic Resonance Imaging

Bayer Reports the Initiation of the P-III (QUANTI) Trials for Gadoquatrane as a Contrast Agent for Magnetic Resonance Imaging

  • June 28, 2023
Bayer to Initiates P-III Study (FINE-ONE) of Finerenone for the Treatment of Chronic Kidney Disease and Type 1 Diabetes

Bayer to Initiates P-III Study (FINE-ONE) of Finerenone for the Treatment of Chronic Kidney Disease and Type 1 Diabetes

  • June 22, 2023
Bayer Entered into an Exclusive License Agreement with Cedilla Therapeutics to Develop and Commercialize CyclinE1/CDK2 Complex Inhibitors

Bayer Entered into an Exclusive License Agreement with Cedilla Therapeutics to Develop and Commercialize CyclinE1/CDK2 Complex Inh...

  • June 2, 2023
Bayer Entered into a Collaboration Agreement with Bicycle Therapeutics for the Development of Novel Targeted Radionuclide Therapies in Oncology

Bayer Entered into a Collaboration Agreement with Bicycle Therapeutics for the Development of Novel Targeted Radionuclide Therapie...

  • May 11, 2023
Bayer’s Kerendia (finerenone) Receives NICE Recommendation for Chronic Kidney Disease Associated with Type 2 Diabetes

Bayer’s Kerendia (finerenone) Receives NICE Recommendation for Chronic Kidney Disease Associated with Type 2 Diabetes

  • March 27, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.